Kazia Therapeutics

Kazia Therapeutics is a biotechnology company focused on oncology, dedicated to developing innovative anti-cancer drugs. Kazia Therapeutics collaborates with top scientists, clinicians, and investors worldwide. Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, currently in development for the treatment of various forms of brain cancer. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, licensed from Evotec SE in April 2021. Preclinical data show that EVT801 is active against multiple tumor types and provides evidence of synergy with immuno-oncology drugs.